智通财经APP讯，欧化(01711)发布截至2025年9月30日止6个月的中期业绩公告，该集团取得收入6680.4 万港元，同比减少15.84%;净亏损265.8万港元，同比减少76.08%;每股基本亏损0.33港仙。 ...

欧化(01711)发布截至2025年9月30日止6个月的中期业绩公告，该集团取得收入6680.4万港元，同比减少 15.84%;净亏损265.8万港元，同比减少76.08%;每股基本亏损0.33港仙。 ...

2025/2026年度之中期業績公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：1711） 歐化國際有限公司 2025/2026年度之中期業績公告 – 1 – 業務回顧 本集團乃一家主要由歐洲進口優質傢俬的領先零售商。本公司自2018年1月起在香港 聯合交易所有限公司主板上市。 由於本集團實施了有效的成本節省措施，其於本期間的淨虧損大幅收窄至2,700,000 港元（2024年：11,100,000港元）。每股基本虧損為0.33港仙（2024年：1.39港仙）。 歐化國際有限公司（「本公司」）之董事會（「董事會」或「董事」）宣佈本公司及其附屬公 司（統稱「本集團」）截至2025年9月30日止六個月（「本期間」）之未經審核簡明綜合業 績。 管理層討論及分析 於本期間，經營環境仍然充滿挑戰且複雜多變，因此本集團的總收入減少至66,800,000 港元（2024年：79,400,000港元）。毛利為37,20 ...

Core Viewpoint - The company, Euroasia (01711.HK), has announced a board meeting scheduled for November 21, 2025, to approve the interim results announcement for the six months ending September 30, 2025, and to consider the potential distribution of an interim dividend [1] Group 1 - The board meeting will take place on a Friday [1] - The interim results will cover the period ending September 30, 2025 [1] - The company will consider whether to declare an interim dividend during this meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 歐化國際有限公司 公司秘書 陳麗艷 香港，2025年11月11日 | 楊政龍先生 | | --- | | 陳傳賢先生 | | 范敏嫦女士 | 董事會會議日期 | 獨立非執行董事： | 陳綺雯女士 | | --- | --- | | | 招健暉先生 | | | 伍海于先生 | 歐化國際有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於2025年11 月21日（星期五）舉行董事會會議，藉以（其中包括）批准刊發本公司及其附屬公司 截至2025年9月30日止六個月之中期業績公告，以及考慮會否派發中期股息。 於本公告日期，董事會成員為 : 執行董事： （於香港註冊成立之有限公司） （股份代號: 1711） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年10月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 歐化國際有限公司 | | | 呈交日期: | 2025年11月3日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01711 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 800,000,000 | | 0 | | 800,000,000 | | 增加 / 減少 (-) | | | 0 | | 0 ...

Core Viewpoint - Jacobson Pharma and Genetron Holdings announced a new licensing agreement with Europharma, which will provide manufacturing space for Genetron in Hong Kong, effective from December 1, 2025, to January 27, 2028, with a monthly fee of HKD 247,000 [1] Group 1 - The 2025 Europharma licensing agreement is established due to the expiration of a previous licensing agreement in November 2025 [1] - Europharma is a wholly-owned subsidiary of Jacobson Pharma, while Europharma (Hong Kong) is a wholly-owned subsidiary of Genetron Holdings [1] - Since 2007, Europharma has been leasing factory space in the Science Park for pharmaceutical manufacturing [1] Group 2 - The new licensing arrangement will generate rental income from unused factory space for Europharma and provide suitable manufacturing facilities for Europharma (Hong Kong) [1] - Relocating Europharma (Hong Kong)'s existing facilities that comply with pharmaceutical production quality management standards is costly and time-consuming [1] - The 2025 Europharma licensing agreement allows Europharma (Hong Kong) to continue operations without interruption and avoid relocation expenses [1]

Core Viewpoint - Jacobson Pharmaceutical's licensing agreement with Europharma will expire on November 30, 2025, leading to a new licensing agreement effective from December 1, 2025, to January 27, 2028, with a monthly fee of HKD 247,000 [1] Group 1 - The new licensing agreement was established on October 28, 2025, between Europharma and Europharma (Hong Kong) [1] - The monthly licensing fee under the new agreement is set at HKD 247,000 [1] - The duration of the new agreement spans from December 1, 2025, to January 27, 2028 [1]

Group 1 - The core point of the article is that Euroasia (01711) expects a significant reduction in net loss for the six months ending September 30, 2025, to no more than HKD 3 million, compared to HKD 11 million in 2024, primarily due to effective cost control measures implemented during this period [1]

Core Viewpoint - The company expects a significant reduction in net loss for the six months ending September 30, 2025, to not more than HKD 3 million, compared to a loss of HKD 11 million in 2024, primarily due to effective cost control measures implemented during this period [1]. Financial Performance - The anticipated net loss for the upcoming period is projected to be not more than HKD 3 million [1]. - In comparison, the net loss for the same period in 2024 was HKD 11 million, indicating a substantial improvement [1]. Cost Management - The improvement in financial performance is attributed to the company's effective cost control measures [1]. Future Reporting - The company has not yet finalized the unaudited interim results for the period and plans to publish these results in late November 2025 [1].